PharmaTher Holdings Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Fabio Chianelli

Amministratore delegato

CA$320.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.3yrs
Proprietà del CEO	17.5%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why We're Not Too Worried About PharmaTher Holdings' (CSE:PHRM) Cash Burn Situation

Dec 31

AMMINISTRATORE DELEGATO

Fabio Chianelli (46 yo)

4.3yrs

Mandato

CA$320,000

Compensazione

Mr. Fabio Chianelli is the Founder of PharmaTher Holdings Ltd. (formerly known as Newscope Capital Corporation) (formerly known as PharmaTher Inc.). and serves as its Chief Executive Officer since June 03,...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Fabio Chianelli	Founder	4.3yrs	CA$320.00k	17.51% CA$ 3.4m
Beverly Incledon	Independent Director	4.3yrs	Nessun dato	Nessun dato
Carlo Sansalone	Independent Director	4.3yrs	Nessun dato	1.13% CA$ 220.0k
Christian Scovenna	Independent Director	4.3yrs	Nessun dato	Nessun dato

4.3yrs

Durata media

48yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PHRM sono considerati esperti (durata media dell'incarico 4.2 anni).

PharmaTher Holdings Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd., Annual General Meeting, Nov 24, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

PharmaTher Holdings Ltd., Annual General Meeting, Nov 25, 2022

Recent updates

PharmaTher Holdings Ltd., Annual General Meeting, Nov 29, 2024

PharmaTher Holdings Ltd. Announces Update on FDA New Drug Application for Ketamine

PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

New major risk - Share price stability

PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine

Here's Why We're Not Too Worried About PharmaTher Holdings' (CSE:PHRM) Cash Burn Situation

New major risk - Financial position

PharmaTher Holdings Ltd. Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

PharmaTher Holdings Ltd., Annual General Meeting, Nov 24, 2023

PharmaTher Holdings Ltd. Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

New major risk - Market cap size

PharmaTher Holdings Ltd. Announces Positive Research Results for PharmaPatch with N,N-Dymethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

PharmaTher Holdings Ltd. Initiates Filing of Abbreviated New Drug Application for KETARX to the FDA

PharmaTher Holdings Ltd. Announces FDA Approval for KETARX

PharmaTher Holdings Ltd. Submits FDA Meeting Package to Discuss 505(B)(2) Pathway for New Drug Application of Ketarx (Ketamine) On-Body Pump System

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX (Ketamine) in Parkinson's Disease

PharmaTher Holdings Ltd. Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

High number of new and inexperienced directors

Pharmather Holdings Ltd. Announces A Poster Presentation of the Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’S Disease

High number of new and inexperienced directors

PharmaTher Holdings Ltd. to Present Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease At the MDS International Congress of Parkinson's Disease and Movement Disorders

PharmaTher Holdings Ltd., Annual General Meeting, Nov 25, 2022

PharmaTher Holdings Ltd. Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with Ketarx Ketamine Patch

PharmaTher Holdings Ltd Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders

PharmaTher Holdings Ltd. Announces Positive Results from Study for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Announces Positive Results from Study of Ketabet™ for Depression

PharmaTher Holdings Ltd. Announces FDA Approval of Investigational New Drug Application for Ketamine to Treat ALS

PharmaTher Holdings Ltd. Announces Publication of Research Data for Ketabet™

PharmaTher Holdings Ltd Provides Product Pipeline Update and Expected Milestones for 2022

PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch

PharmaTher Holdings Ltd. Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

PharmaTher Holdings Ltd. announced that it expects to receive CAD 10 million in funding

Pharmather Holdings Ltd. Provides Product Pipeline Update

PharmaTher Holdings Ltd. Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

PharmaTher Holdings Ltd. Files FDA Pre-IND Meeting Request and Briefing Package for KETABET™ to Treat Depression

Pharmather Holdings Ltd. Provides Research and Development Update and Milestones for 2021

Pharmather Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease

PharmaTher Announces FDA Approval of Ketamine IND in the Treatment of Parkinson’s Disease

PharmaTher Holdings Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™

New 90-day low: CA$0.24

PharmaTher Inc. Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig's Disease

PharmaTher Announces Research Collaboration with Terasaki Institute for Novel Microneedle Delivery of Psychedelic Pharmaceuticals

Newscope Capital Corporation Announces Successful Completion of a Type B Pre-Investigational New Drug

New 90-day high: CA$0.41

Revive Therapeutics Ltd. Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Pharmather Inc. Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the Treatment of Parkinson's Disease

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media